ProtoKinetix

ProtoKinetix ROCE

The Return on Capital Employed (ROCE) of ProtoKinetix (PKTX) as of Nov 19, 2026 is -132.12 %. In the previous year, Return on Capital Employed (ROCE) was -90.91 % — a change of 45.33% (lower).

ROCE

-132.12 %

YoY

45.33%

Last updated:

In 2025, ProtoKinetix's return on capital employed (ROCE) was -132.12 %, a 45.33% increase from the -90.91 % ROCE in the previous year.

The ProtoKinetix ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-494.39 USD
Jan 1, 2019
-749.11 USD
Jan 1, 2020
-1,801.89 USD
Jan 1, 2021
-659.84 USD
Jan 1, 2022
-438.84 USD
Jan 1, 2023
-84.20 USD
Jan 1, 2024
-90.91 USD
Jan 1, 2025
-132.12 USD
The ProtoKinetix ROCE history
YEARROCEYoY
-132.12 %+45.33%
-90.91 %+7.97%
-84.20 %-80.81%
-438.84 %-33.49%
-659.84 %-63.38%
-1,801.89 %+140.54%
-749.11 %+51.52%
-494.39 %+22.14%
-404.78 %+31.90%
-306.89 %-1.36%
-311.13 %-447.05%
89.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling ProtoKinetix's Return on Capital Employed (ROCE)

ProtoKinetix's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing ProtoKinetix's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

ProtoKinetix's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in ProtoKinetix’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about ProtoKinetix stock

Return on Capital Employed (ROCE) of ProtoKinetix is -132.12 % in 2025.

Return on Capital Employed (ROCE) of ProtoKinetix changed from -90.91 % to -132.12 %, representing a 45.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s ProtoKinetix with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ProtoKinetix

All Key Metrics — ProtoKinetix